Skip to main content

Biogen’s pivotal moment: Will the FDA approve the experimental — and controversial — Alzheimer’s-disease drug aducanumab?

U.S. regulators are expected to decide whether to approve Biogen’s experimental Alzheimer’s disease drug sometime this week, a decision that could send the company’s stock price soaring or tumbling depending on the outcome.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.